Webb23 juni 2024 · Tol Trimborn, Chief Executive Officer of CellPoint, said: "CellPoint's T-cell therapies have enormous potential for treating various cancers. Webb7 apr. 2024 · Tol Trimborn, Chief Executive Officer of CellPoint, said: "We are very pleased to add Pregene's novel anti-BCMA CAR-T therapy to our CAR-T portfolio and look forward …
Open X-Cellerator Community September 2024 - World Courier
Webb23 juni 2024 · Tol Trimborn, Chief Executive Officer of CellPoint, said: “CellPoint’s T-cell therapies have enormous potential for treating various cancers. This agreement will allow us to accelerate our path to the clinic, treating more patients sooner, and help to solve the key issues facing CAR-T therapeutics. Webb21 juni 2024 · Our novel decentralized manufacturing and supply model is designed to address these limitations and deliver CAR-T cells at point-of-care, in or near the hospital, thereby offering the potential to significantly shorten time to treatment to one week as compared to the current industry standard of over a month,” added Dr. Tol Trimborn, co … magnetic speakers mashable
Venture Challenge Spring 2016: Meet the teams - Work
Webb9 feb. 2024 · Tol Trimborn: ,,Je transporteert de cellen niet naar een fabriek, maar doet het in de labs van de ziekenhuizen zelf, met deze gesloten en automatische bioreactor.’’ Dit … Webb23 juni 2024 · Tol Trimborn, Chief Executive Officer of CellPoint, said: “CellPoint’s T-cell therapies have enormous potential for treating various cancers. This agreement will … Webb22 juni 2024 · Directeur Tol Trimborn van Cellpoint voorziet een versnelling van de ontwikkeling van de kankertherapieën dankzij de overname door Galapagos. Ⓒ Cellpoint … nytimes election va